X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.biospectrumasia.com/news/25/24098/eisais-antiepileptic-drug-fycompa-injection-formulation-launches-in-japan.html
https://www.globenewswire.com/news-release/2023/08/14/2724366/13009/en/Catalyst-Pharmaceuticals-Announces-Multiple-Abstracts-on-FYCOMPA-Perampanel-from-Eisai-Co-Ltd-to-be-Presented-at-the-35th-International-Epilepsy-Congress.html
https://www.expresspharma.in/akums-gets-dcgi-approval-for-perampanel-oral-suspension/
https://www.globenewswire.com/news-release/2023/04/20/2650960/13009/en/Catalyst-Pharmaceuticals-Announces-Third-Party-Abstracts-on-FYCOMPA-Perampanel-to-be-Presented-at-the-Upcoming-American-Academy-of-Neurology-2023-Annual-Meeting.html
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-perampanel-oral-suspension-68385.pdf
https://www.pharmaceutical-technology.com/news/catalyst-buy-eisais-fycompa/
https://www.pharmaceutical-technology.com/news/catalyst-buy-eisais-fycompa/
https://www.globenewswire.com/news-release/2022/12/19/2576663/0/en/Catalyst-Pharmaceuticals-to-Acquire-U-S-Commercial-Rights-to-FYCOMPA-Perampanel-CIII-From-Eisai-Co-Ltd.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209801
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209801
https://www.prnewswire.com/news-releases/eisai-presents-its-largest-real-world-study-of-anti-epileptic-drug-fycompa-perampanel-across-patient-types-at-the-2021-american-epilepsy-society-aes-annual-meeting-301439328.html
https://www.prnewswire.com/news-releases/eisai-to-present-real-world-evidence-and-convulsive-seizure-freedom-data-evaluating-fycompa-perampanel-across-patient-types-at-75th-american-epilepsy-society-aes-annual-meeting-301435570.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209877
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209801
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209538
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209801
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209877
https://www.fdanews.com/articles/200019-european-commission-approves-anti-epileptic-fycompa-as-adjunct-for-children
https://www.biospectrumasia.com/news/25/16769/eisai-receives-emas-chmp-approval-for-antiepileptic-agent-fycompa-for-pediatric-use.html#:~:text=Eisai%20Co.%2C%20Ltd.%20on,house%20discovered%20and%20developed%20anti%2D
https://www.biospectrumasia.com/news/25/15213/eisai-launches-antiepileptic-drug-in-china.html
https://www.prnewswire.com/news-releases/eisai-to-present-convulsive-seizure-freedom-data-evaluating-fycompa-in-newly-diagnosed-partial-onset-patients-at-upcoming-american-epilepsy-society-annual-meeting-300964232.html
http://www.pharmafile.com/news/531196/china-approves-eisais-fycompa-partial-onset-epileptic-seizures
https://www.prnewswire.com/news-releases/lower-hospitalization-rates-in-epilepsy-patients-treated-with-adjunctive-fycompa-perampanel-ciii-300847474.html
https://www.fiercepharma.com/marketing/opdp-rebukes-eisai-sales-rep-letter-serves-as-reminder-to-pharma-docs-are-watching
https://www.prnewswire.com/news-releases/eisai-and-oklahoma-health-care-authority-enter-value-based-agreement-for-fycompa-300737009.html
https://www.prnewswire.com/news-releases/eisai-receives-fda-priority-review-designation-for-fycompa-perampanel-ciii-pediatric-indications-supplemental-new-drug-application-snda-300656500.html
https://www.prnewswire.com/news-releases/eisai-submits-supplemental-new-drug-application-snda-to-fda-for-fycompa-perampanel-pediatric-indications-300622275.html
https://www.biospectrumasia.com/news/25/9360/eisai-introduces-first-in-class-epilepsy-treatment-fycompa-perampanel-in-india.html
http://www.prnewswire.com/news-releases/fda-approves-eisais-fycompa-perampanel-for-use-as-monotherapy-for-the-treatment-of-partial-onset-seizures-300494943.html
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/japanese-companies-make-cautious-return-to-indian-pharma-market/articleshow/56320837.cms
http://www.fiercepharma.com/pharma/already-a-hated-pricing-foe-germany-eyes-stiffer-limits-new-controls
http://www.prnewswire.com/news-releases/eisai-announces-initiation-of-two-phase-3-clinical-trials-with-fycompa-perampanel-300353409.html
http://www.prnewswire.com/news-releases/eisai-submits-supplemental-application-to-fda-for-use-of-its-antiepileptic-drug-fycompa-perampanel-as-monotherapy-for-the-treatment-of-partial-onset-seizures-300334071.html
http://www.prnewswire.com/news-releases/fycompa-perampanel-oral-suspension-now-available-as-an-option-for-patients-with-epilepsy-who-may-have-difficulty-swallowing-tablets-or-prefer-liquids-300284963.html
https://www.pharmacompass.com/pdf/news/eisais-fycompa-perampanel-approved-in-us-for-epilepsy-1462269204.pdf
http://www.prnewswire.com/news-releases/presentados-nuevos-datos-de-practica-clinica-sobre-el-uso-de-zebinix-acetato-de-eslicarbazepina-para-tratar-las-crisis-de-inicio-parcial-en-la-reunion-anual-de-la-sociedad-americana-de-epilepsia-aes-561277221.html
http://www.prnewswire.com/news-releases/presentacion-de-datos-agrupados-en-fase-iii-en-la-reunion-anual-de-la-sociedad-americana-de-epilepsia-aes-sobre-el-uso-de-fycompa-perampanel-para-tratar-crisis-tonico-clonicas-generalizadas-primarias-y-secundarias-561194861.html
http://www.prnewswire.com/news-releases/zebinix-acetate-deslicarbazepine-dans-la-prise-en-charge-des-crises-partielles-depilepsie-nouvelles-analyses-de-donnees-de-vie-reelle-presentees-lors-du-congres-annuel-de-lamerican-epilepsy-society-aes-560733251.html
http://www.prnewswire.com/news-releases/donnees-regroupees-de-phase-iii-presentees-lors-du-congres-2015-de-laes-american-epilepsy-society-sur-lutilisation-de-fycompa-perampanel-dans-le-traitement-des-crises-tonico-cloniques-generalisees-secondaires-560864211.html
http://www.fiercepharma.com/story/struggling-eisai-looks-help-china-new-generics-deal/2015-12-03
http://www.prnewswire.com/news-releases/eisai-presents-data-on-perampanel-and-first-and-largest-us-study-on-caregiver-burden-in-epilepsy-at-the-69th-annual-american-epilepsy-society-meeting-300186544.html
http://www.prnewswire.co.uk/news-releases/eisai-kundigt-anderung-des-zugangs-zu-fycompa-perampanel-in-deutschland-an-540721951.html
http://www.prnewswire.com/news-releases/eisai-announces-fda-acceptance-of-nda-for-the-review-of-fycompa-perampanel-oral-suspension-for-adjunctive-therapy-in-the-treatment-of-partial-onset-seizures-and-primary-generalized-tonic-clonic-seizures-in-patients-with-epileps-300141780.html
http://www.pharmatimes.com/Article/15-09-10/Phase_III_data_back_efficacy_of_Fycompa_in_epilepsy.aspx?
http://www.prnewswire.com/news-releases/los-resultados-finales-del-estudio-epos-presentados-en-el-congreso-internacional-de-epilepsia-iec-muestran-que-el-tratamiento-adyuvante-con-zebinix-acetato-de-eslicarbazepina-mejora-la-calidad-de-vida-525801711.html
Market Place
Share 
